Intrinsiqq
XBiotech Inc. logo

XBiotech Inc. Quality Score

XBIT

Compare
Quality16

Weak across most dimensions. This doesn't mean avoid, but the burden of proof is on the bull case.

Broad-market heuristics · Not a buy/sell signal

Valuation and growth

Earnings Multiple
0/100
-1.2x

Negative earnings, no valuation support

Cash Flow Multiple
0/100
-1.3x

Negative FCF, no valuation support

Cash Flow Growth
0/100
Negative FCF

FCF negative, burning cash after capex

Business Quality & Capital Allocation

Share Dilution
60/100
0.2%

Mild dilution under 2%

Capital Structure
100/100
-$126M

Net cash position, no leverage concern

2022
$217M
$0.00
2023
$200M
$0.00
2024
$173M
$10.0M
2025
$126M
$0.00
TTM
$126M
$0.00
CashDebt
Return on Capital
0/100
-26.4%

Below 8%, may not cover cost of capital

Customize WeightsPremiumUpgrade

XBiotech (XBIT) quality: score, margins and returns

XBiotech (XBIT) scores 16/100 on Intrinsiqq's quality score (a lower-quality business), a weighted blend of 4 metrics each scored 0 to 100 and -26.4% ROIC. Every metric is computed from company filings; this is analysis, not investment advice.

Frequently asked

Is XBiotech (XBIT) a high-quality business?+

XBiotech scores 16 out of 100 on Intrinsiqq's quality score, a weighted blend of 4 metrics each scored 0 to 100, which rates it a lower-quality business on these measures. Recent figures include a -26.4% return on invested capital. Quality and price are separate questions: even a great business can be a poor investment if you overpay, so read this score alongside the valuation. The metric-by-metric breakdown is on this scorecard.

What does XBiotech's quality score measure?+

Intrinsiqq's quality score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, change in share count, and balance-sheet strength, each computed from XBIT's company filings rather than opinion or sentiment. A higher score means a more durable, capital-efficient business; it is not a buy or sell signal. Open each metric on this page to see exactly where XBiotech scores well and where it falls behind.

What is XBiotech's return on invested capital (ROIC)?+

XBiotech earns about -26.4% on its invested capital, which is weak. ROIC measures how much profit a company generates per dollar put to work; sustained ROIC above its cost of capital is one of the clearest signs of a real competitive moat. Compare it to XBIT's margins and growth on this scorecard to judge durability.

How the market compares: US profitability statistics

Peers

Biotechnology · Pick stocks to compare with XBIT

CompareIntrinsic value
NEWBRY.XSTONewbury Pharmaceuticals AB
€0.11+0.91%40
HPHA.XETRHeidelberg Pharma AG
€2.01-2.90%10
MEDCL.XPARMedincell SA
€26.70-2.05%40
ZTEKZentek Ltd.
€0.33-0.60%40
XTXXFAdastra Holdings Ltd.
€0.08+0.00%40
XRTXXORTX Therapeutics Inc.
$0.84-5.73%10
VALNValneva SE Sponsored ADR
$5.16-3.82%0
TRIBTrinity Biotech plc Sponsored ADR
$6.24+13.66%10

Held by ETFs

XBIT is in 1 US ETF. The largest of them, with XBIT's weight in each:

Spot a number that looks wrong?

Download this analysis as a PDF (Pro)

Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing XBIT

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

MarketsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.